Neogenomics Inc Q3 2020 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: David Michael Westenberg - Guggenheim Securities, LLC, Research Division - Analyst : I don't want to belabor the macro point, but I am getting questions on that. So I just wanted to maybe ask a different way. Can you talk about the volume recovery in community versus academic versus maybe private practice? Or if there's any differences in recover regionally in terms of percentage? And then maybe kind of give us some color in terms of percentage exposure to those end markets for NeoGenomics.

Question: David Michael Westenberg - Guggenheim Securities, LLC, Research Division - Analyst : Great. And then just maybe a question for Doug Brown. Are you seeing in terms of the deal pipeline in terms of small regional labs? Are there any change in terms of dynamics there? I mean, I mean, I'm sure they're getting hit with volume, too. They probably have more liquidity concerns or maybe they're having more difficulty accessing capital. And you guys are very well capitalized at $300 million. Just any changes in those kind of dynamics we should think about? And that's my last one.

Question: Jacob K. Johnson - Stephens Inc., Research Division - Analyst : Maybe a bigger picture question on having the strategy in both Clinical Services and Pharma Services. I think companion diagnostics represents maybe a key synergy there. Can you just give us an update on the companion diagnostics efforts and maybe how many of these you're working on right now in Pharma Services?

Question: Jacob K. Johnson - Stephens Inc., Research Division - Analyst : Got it. And then maybe on the Clinical Services side, I imagine COVID-19 is taking up a disproportionate amount of your time. But in clinical services, after you've integrated Genoptix, are there any operational areas that you've been focused on recently, admittedly in the midst of a pandemic, I think billing and collecting is always an area of focus, but anything else?